Psoriasis combo therapy trial ends early: what happened?
NCT ID NCT02829424
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding low-dose methotrexate to standard anti-TNF therapy could improve and extend the response in adults with moderate to severe psoriasis. The trial planned to enroll 78 participants but was terminated early. The main goal was to see how long patients maintained at least a 75% improvement in their psoriasis symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Methotrexate
What this could lead to
If it worked, this could show that adding methotrexate helps people with psoriasis maintain a better response to anti-TNF drugs for longer.
What could go wrong
The trial was terminated early with only 78 participants, so results are limited. It is a Phase 4 study, meaning the drugs are already approved, so no breakthrough is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique Hôpitaux de Marseille
Marseille, 13385, France